Zhejiang Huahai Pharmaceutical Co., Ltd. Class ASSE: 600521

Announcement on Subsidiary HB0025 Injection Initiating Endometrial Cancer Phase III Clinical Trial

· Issued by Zhejiang Huahai Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Subsidiary HB0025 Injection Initiating Endometrial Cancer Phase III Clinical Trial

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment